Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice
-
Add time:09/26/2019 Source:sciencedirect.com
A fixed dose combination of bupropion (BPP) and naltrexone (NTX), Contrave®, is an FDA approved pharmacotherapy for the treatment of obesity. A recent study found that combining BPP with low-dose NTX reduced alcohol drinking in alcohol-preferring male rats. To explore potential pharmacological effects of the BPP + NTX combination on alcohol drinking, both male and female C57Bl/6J mice were tested on one-week drinking-in-the dark (DID) and three-week intermittent access (IA) models. Neuronal proopiomelanocortin (POMC) enhancer knockout (nPE−/−) mice with hypothalamic-specific deficiency of POMC, and its bioactive peptides melanocyte stimulating hormone and beta-endorphin, were used as a genetic control for the effects of the BPP + NTX. A single administration of BPP + NTX (10 mg/kg + 1 mg/kg) decreased alcohol intake after DID in C57Bl/6J males, but not females. Also in C57Bl/6J males, BPP + NTX reduced intake of the caloric reinforcer sucrose, but not the non-caloric reinforcer saccharin. In contrast, BPP + NTX had no effect on alcohol DID in nPE−/− males. Pretreatment with the selective melanocortin 4 receptor (MC4R) antagonist HS014 reversed the anti-dipsogenic effect of BPP + NTX on alcohol DID in C57Bl/6J males. In the 3-week chronic IA model, single or repeated administrations for four days of BPP + NTX reduced alcohol intake and preference in C57Bl/6J males only. The behavioral measures observed in C57Bl/6J mice provide clear evidence that BPP + NTX profoundly reduced alcohol drinking in males, but the doses tested were not effective in females. Furthermore, our results suggest a hypothalamic POMC/MC4R-dependent mechanism for the observed BPP + NTX effects on alcohol drinking in male mice.
We also recommend Trading Suppliers and Manufacturers of Naltrexone hydrochloride (cas 16676-29-2). Pls Click Website Link as below: cas 16676-29-2 suppliers
Prev:Original articleSimultaneous determination of naltrexone and bupropion in their co-formulated tablet utilizing green chromatographic approach with application to human urine
Next:Design of controlled release inert matrices of Naltrexone hydrochloride (cas 16676-29-2) based on percolation concepts) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Design of controlled release inert matrices of Naltrexone hydrochloride (cas 16676-29-2) based on percolation concepts09/27/2019
- Original articleSimultaneous determination of naltrexone and bupropion in their co-formulated tablet utilizing green chromatographic approach with application to human urine09/25/2019
- Research ArticlesStructural characterization of anhydrous naloxone‐ and Naltrexone hydrochloride (cas 16676-29-2) by high resolution laboratory X‐ray powder diffraction and thermal analysis09/24/2019
- Niosomes and discomes for ocular delivery of Naltrexone hydrochloride (cas 16676-29-2): Morphological, rheological, spreading properties and photo-protective effects09/10/2019
- Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-Naltrexone hydrochloride (cas 16676-29-2): Fabrication, mechanical properties, mucoadhesion, tolerability and stability studies09/09/2019
- Hydrogels for diabetic eyes: Naltrexone loading, release profiles and cornea penetration09/08/2019
- Pharmaceutics, Preformulation and Drug DeliveryDesign and Evaluation of Controlled-Release Niosomes and Discomes for Naltrexone hydrochloride (cas 16676-29-2) Ocular Delivery09/07/2019
- In-vivo study of Naltrexone hydrochloride (cas 16676-29-2) release from an in-situ forming PLGA-PEG-PLGA system in the rabbit09/06/2019
-
Health and Chemical more >